THE TREATMENT OF 45 PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA WITH LOW-DOSES OF INTERFERON-ALPHA-2A AND ETRETINATE

被引:60
作者
DRENO, B
CLAUDY, A
MEYNADIER, J
VERRET, JL
SOUTEYRAND, P
ORTONNE, JP
KALIS, B
GODEFROY, WY
BEERBLOCK, K
THILL, L
机构
[1] LAB ROCHE,NEUILLY SUR SEINE,FRANCE
[2] CHU ST ETIENNE,DEPT DERMATOL,ST PRIEST ENJAREZ,FRANCE
[3] CHU MONTPELLIER,DEPT DERMATOL,F-34059 MONTPELLIER,FRANCE
[4] CHU ANGERS,DEPT DERMATOL,F-49036 ANGERS,FRANCE
[5] CHU CLERMONT FERRAND,DEPT DERMATOL,F-63003 CLERMONT FERRAND,FRANCE
[6] CHU NICE,DEPT DERMATOL,NICE,FRANCE
[7] CHU REIMS,DEPT DERMATOL,F-51100 REIMS,FRANCE
关键词
D O I
10.1111/j.1365-2133.1991.tb14772.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Forty-five patients with cutaneous T-cell lymphomas (CTCL), 32 with mycosis fungoides (MF) and 13 with Sezary syndrome (SS), were treated with interferon-alpha-2a (IFN-alpha-2a) (6-9 x 10(6) IU daily) for 3 months. Those responding to treatment were then treated with interferon-alpha alone (6-9 x 10(6) IU three times weekly), and non-responders received a combination of etretinate (0.5 mg/kg/day) and IFN-alpha-2a in similar concentrations. After 12 months of treatment, 28/45 patients (62.2%) were in complete or partial (> 50%) remission. Of these, 1 7 (60.7%) were receiving IFN-alpha alone and 11 the combined interferon-retinoid therapy. Of the patients with MF stage I and II, 20/25 were responders (12 receiving IFN-alpha alone and eight on combined therapy), whereas only 8/20 with stage IV or SS responded to treatment (five receiving IFN-alpha-2a alone and three combined therapy). These results suggest that the association of etretinate with low-dose recombinant IFN-alpha-2a is an effective means of treating epidermotropic CTCL, particularly in the early stages.
引用
收藏
页码:456 / 459
页数:4
相关论文
共 16 条
[1]  
BRAATHEN LR, 1989, J DERMATOL TREAT, V1, P29
[2]   RECOMBINANT LEUKOCYTE A-INTERFERON - AN ACTIVE AGENT IN ADVANCED CUTANEOUS T-CELL LYMPHOMAS [J].
BUNN, PA ;
FOON, KA ;
IHDE, DC ;
LONGO, DL ;
EDDY, J ;
WINKLER, CF ;
VEACH, SR ;
ZEFFREN, J ;
SHERWIN, S ;
OLDHAM, R .
ANNALS OF INTERNAL MEDICINE, 1984, 101 (04) :484-487
[3]   TREATMENT OF CUTANEOUS LYMPHOMA WITH ETRETINATE [J].
CLAUDY, AL ;
ROUCHOUSE, B ;
BOUCHERON, S ;
LEPETIT, JC .
BRITISH JOURNAL OF DERMATOLOGY, 1983, 109 (01) :49-56
[4]  
DICKEN CH, 1982, MAYO CLIN PROC, V57, P51
[5]   LOW-DOSE RECOMBINANT INTERFERON-ALPHA IN THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMAS [J].
DRENO, B ;
GODEFROY, WY ;
FLEISCHMANN, M ;
BUREAU, B ;
LITOUX, P .
BRITISH JOURNAL OF DERMATOLOGY, 1989, 121 (04) :543-544
[6]  
HAGBERG H, 1988, EUR J HAEMATOL, V40, P31
[7]   PHOTOCHEMOTHERAPY FOR CUTANEOUS T-CELL LYMPHOMA - A FOLLOW-UP-STUDY [J].
HONIGSMANN, H ;
BRENNER, W ;
RAUSCHMEIER, W ;
KONRAD, K ;
WOLFF, K .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1984, 10 (02) :238-245
[8]  
KESSLER JF, 1983, LANCET, V1, P1345
[9]  
MAHRLE G, 1987, Dermatologica (Basel), V175, P145
[10]  
MOLIN L, 1980, ACTA DERM-VENEREOL, V61, P47